Elkfork Partners’s Ascendis Pharma A/S ASND Stock Holding History

Elkfork Partners’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$537K	Buy	5,576 +680	+14%	+$75.9K	0.01%	554
2019 Q2	$564K	Buy	4,896 +306	+7%	+$36.6K	0.01%	543
2019 Q1	$540K	Sell	4,590 -1,802	-28%	-$158K	0.01%	540
2018 Q4	$400K	Sell	6,392 -4,692	-42%	-$295K	0.01%	580
2018 Q3	$785K	Buy	11,084 +340	+3%	+$23.4K	0.02%	448
2018 Q2	$715K	Buy	10,744 +1,156	+12%	+$76K	0.02%	431
2018 Q1	$627K	Buy	+9,588	New	+$539K	0.02%	465

Other funds holding ASND

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Elkfork Partners's ASND Position: Q3 2019 in Review

Elkfork Partners increased its Ascendis Pharma A/S (ASND) stake by 14% in Q3 2019, buying an estimated $75.9K and bringing the position to 5,576 shares worth $537K. The position accounts for 0.01% of the portfolio, ranked #554.

Elkfork Partners first reported a position in ASND in Q1 2018 and has held it in 7 quarters since. The position peaked at $785K in Q3 2018. 129 funds tracked by Wall St. Rank hold ASND as of Q3 2019.

Elkfork Partners held 5,576 shares of Ascendis Pharma A/S worth $537K as of Q3 2019.
Elkfork Partners bought 680 Ascendis Pharma A/S shares in Q3 2019, an estimated $75.9K.
Ascendis Pharma A/S made up 0.01% of Elkfork Partners's portfolio in Q3 2019, its #554 holding.
Elkfork Partners first reported a position in Ascendis Pharma A/S in Q1 2018 and has held it in 7 quarters since.
Elkfork Partners's Ascendis Pharma A/S position peaked at $785K in Q3 2018.
129 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2019.

Based on Elkfork Partners's 13F filing for Q3 2019, filed 14 Nov 2019.